Dylan Dupuis

Stock Analyst at Roth MKM

(2.78)
# 1,982
Out of 4,996 analysts
8
Total ratings
50%
Success rate
43.19%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Dylan Dupuis

Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $28
Current: $2.64
Upside: +960.61%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $6.05
Upside: +81.82%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $7.64
Upside: +201.05%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $25.57
Upside: +25.15%